- Haynes, J., McKee T., Haller A., et al. Administration of Hypoxia-Activated Prodrug Evofosfamide after Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Colorectal Cancer. Clin Cancer Res. 2018 May 1;24(9):2116-2127
- Haller, AC., Tan, W., Payne-Ondracek, R., Underwood, W., Tian, L., Morrison, C. and Li, F. High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate, 2014; 74: 509–519.
- Chang Q, Ling X, Haller AC, Nakahara T, Yamanaka K, Kita A, Koutaku H, Takeuchi M, Brattain M, Li F. “Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter” Int J Biochem Mol Biol. 2012; 3(2):179–197
- Alcasabas P, Ravindranath Y, Goyette G, Haller AC et al. “5,10 -Methylenetetrahydrofolate Reductase (MTHFR) Polymorphisms and the Risk of Acute Lymphoblastic Leukemia (ALL) in Filipino children” Ped Blood and Cancer. 2008 Aug;51(2):178-82
- Haller AC, Kanakapalli, K, Walter R et al. “Transcriptional profiling of degraded RNA in cryopreserved and fixed tissue samples obtained at autopsy” BMC Clinical Pathology 2006, 6:9
Andrew grew up in Detroit, MI and received undergraduate degrees from Michigan State University in Biochemistry and Psychology and a graduate degree in Toxicology from Wayne State. He performed his PhD in Molecular Pharmacology and Cancer Therapeutics at SUNY Buffalo and Roswell Park Cancer Institute studying mechanisms of drug resistance and cancer metastasis. In Buffalo he fell in love with the city of Toronto and immigrated to Canada to Post-Doc at the Princess Margaret Cancer Center. His research there sat at the intersection of hypoxia, metabolism, and cancer stem cells. Now he is the Industry Outreach Associate at Clinical Trials Ontario where he leverages a deep network of connections to help companies navigate Ontario’s clinical research environment.